NSE - Delayed Quote INR

Caplin Point Laboratories Limited (CAPLIPOINT.NS)

Compare
2,373.05
-104.45
(-4.22%)
At close: January 10 at 3:30:02 PM GMT+5:30
Advanced Chart
Loading Chart for CAPLIPOINT.NS
DELL
  • Previous Close 2,477.50
  • Open 2,454.00
  • Bid --
  • Ask --
  • Day's Range 2,350.00 - 2,463.65
  • 52 Week Range 1,225.00 - 2,641.00
  • Volume 160,921
  • Avg. Volume 181,791
  • Market Cap (intraday) 180.433B
  • Beta (5Y Monthly) 0.40
  • PE Ratio (TTM) 36.76
  • EPS (TTM) 64.55
  • Earnings Date Feb 7, 2025 - Feb 11, 2025
  • Forward Dividend & Yield 5.00 (0.21%)
  • Ex-Dividend Date Sep 23, 2024
  • 1y Target Est 2,348.33

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

www.caplinpoint.net

3,406

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

More about Caplin Point Laboratories Limited

Recent News: CAPLIPOINT.NS

View More
View More

Performance Overview: CAPLIPOINT.NS

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

CAPLIPOINT.NS
6.50%
S&P BSE SENSEX
1.11%

1-Year Return

CAPLIPOINT.NS
64.74%
S&P BSE SENSEX
8.39%

3-Year Return

CAPLIPOINT.NS
181.23%
S&P BSE SENSEX
29.52%

5-Year Return

CAPLIPOINT.NS
739.24%
S&P BSE SENSEX
86.67%

Compare To: CAPLIPOINT.NS

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

CAPLIPOINT.NS
Caplin Point Laboratories Limited
2,373.05
-4.22%
Mkt Cap INR 180.433B
Industry Drug Manufacturers—Specialty & Generic
AJANTPHARM.NS
Ajanta Pharma Limited
2,834.20
-3.44%
Mkt Cap INR 354.207B
Industry Drug Manufacturers—Specialty & Generic
INNOVACAP.NS
Innova Captab Limited
1,081.55
-3.46%
Mkt Cap INR 61.892B
Industry Drug Manufacturers—Specialty & Generic
APLLTD.NS
Alembic Pharmaceuticals Limited
1,010.05
-4.24%
Mkt Cap INR 198.538B
Industry Drug Manufacturers—Specialty & Generic
SEQUENT.NS
Sequent Scientific Limited
177.68
-4.69%
Mkt Cap INR 44.468B
Industry Drug Manufacturers—Specialty & Generic
GLENMARK.NS
Glenmark Pharmaceuticals Limited
1,541.70
-3.24%
Mkt Cap INR 435.049B
Industry Drug Manufacturers—Specialty & Generic
NATCOPHARM.NS
NATCO Pharma Limited
1,235.55
-4.09%
Mkt Cap INR 221.299B
Industry Drug Manufacturers—Specialty & Generic
MANKIND.NS
Mankind Pharma Limited
2,739.95
-3.12%
Mkt Cap INR 1.13T
Industry Drug Manufacturers—Specialty & Generic
SUVENPHAR.NS
Suven Pharmaceuticals Limited
1,061.95
-3.81%
Mkt Cap INR 270.335B
Industry Drug Manufacturers—Specialty & Generic
BAJAJHCARE.NS
Bajaj HealthCare Limited
536.65
-1.64%
Mkt Cap INR 16.959B
Industry Drug Manufacturers—Specialty & Generic
BLISSGVS.NS
Bliss GVS Pharma Limited
160.47
-3.88%
Mkt Cap INR 16.912B
Industry Drug Manufacturers—Specialty & Generic

Statistics: CAPLIPOINT.NS

View More

Valuation Measures

As of 1/10/2025

  • Market Cap

    180.43B

  • Enterprise Value

    171.72B

  • Trailing P/E

    36.71

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.99

  • Price/Book (mrq)

    7.09

  • Enterprise Value/Revenue

    9.47

  • Enterprise Value/EBITDA

    25.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.93%

  • Return on Assets (ttm)

    12.74%

  • Return on Equity (ttm)

    21.24%

  • Revenue (ttm)

    18.33B

  • Net Income Avi to Common (ttm)

    4.94B

  • Diluted EPS (ttm)

    64.55

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.27B

  • Total Debt/Equity (mrq)

    0.09%

  • Levered Free Cash Flow (ttm)

    1.07B

View More

Research Analysis: CAPLIPOINT.NS

View More
View More

People Also Watch

ERIS.NS Eris Lifesciences Limited
1,287.40
-1.04%
 
APLLTD.NS Alembic Pharmaceuticals Limited
1,010.05
-4.24%
 
JBCHEPHARM.NS J. B. Chemicals & Pharmaceuticals Limited
1,823.05
-2.53%
 
IOLCP.NS IOL Chemicals and Pharmaceuticals Limited
409.15
-3.31%
 
AJANTPHARM.NS Ajanta Pharma Limited
2,834.20
-3.44%
 
AARTIDRUGS.NS Aarti Drugs Limited
429.95
-2.78%
 
SHILPAMED.NS Shilpa Medicare Limited
777.15
-3.91%
 
AVANTIFEED.NS Avanti Feeds Limited
604.90
-2.54%
 
LAURUSLABS.NS Laurus Labs Limited
583.70
-4.79%
 
NATCOPHARM.NS NATCO Pharma Limited
1,235.55
-4.09%
 
ALKEM.NS Alkem Laboratories Limited
5,376.05
-1.43%
 
GRANULES.NS Granules India Limited
593.60
-2.05%
 
SYNGENE.NS Syngene International Limited
859.80
-1.97%
 
THYROCARE.NS Thyrocare Technologies Limited
862.95
-5.63%
 
ASTRAZEN.NS AstraZeneca Pharma India Limited
6,907.35
-2.56%
 
CARBORUNIV.NS Carborundum Universal Limited
1,251.90
-0.88%